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Abstract
Lentiviral vectors (LVs) are potent gene transfer vehicles frequently applied in research and recently also in clinical trials.
Retargeting LV entry to cell types of interest is a key issue to improve gene transfer safety and efficacy. Recently, we have
developed a targeting method for LVs by incorporating engineered measles virus (MV) glycoproteins, the hemagglutinin
(H), responsible for receptor recognition, and the fusion protein into their envelope. The H protein displays a single-chain
antibody (scFv) specific for the target receptor and is ablated for recognition of the MV receptors CD46 and SLAM by point
mutations in its ectodomain. A potential hindrance to systemic administration in humans is pre-existing MV-specific
immunity due to vaccination or natural infection. We compared transduction of targeting vectors and non-targeting vectors
pseudotyped with MV glycoproteins unmodified in their ectodomains (MV-LV) in presence of a-MV antibody-positive
human plasma. At plasma dilution 1:160 MV-LV was almost completely neutralized, whereas targeting vectors showed
relative transduction efficiencies from 60% to 90%. Furthermore, at plasma dilution 1:80 an at least 4-times higher
multiplicity of infection (MOI) of MV-LV had to be applied to obtain similar transduction efficiencies as with targeting
vectors. Also when the vectors were normalized to their p24 values, targeting vectors showed partial protection against a-
MV antibodies in human plasma. Furthermore, the monoclonal neutralizing antibody K71 with a putative epitope close to
the receptor binding sites of H, did not neutralize the targeting vectors, but did neutralize MV-LV. The observed escape from
neutralization may be due to the point mutations in the H ectodomain that might have destroyed antibody binding sites.
Furthermore, scFv mediated cell entry via the target receptor may proceed in presence of a-MV antibodies interfering with
entry via the natural MV receptors. These results are promising for in vivo applications of targeting vectors in humans.
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Introduction
For genetic modification of primary cells, lentiviral vectors (LVs)
are the most suitable vectors as they stably integrate the
transferred gene into the genome of dividing as well as
nonproliferating cells [1]. This property has made LVs ideal gene
delivery vehicles for ex vivo gene therapy in many ongoing clinical
studies [2]. The lentiviral envelope protein can be exchanged with
glycoproteins derived from other viruses (pseudotyping) and
current state-of-the-art vectors are equipped with the glycoprotein
of vesicular stomatitis virus (VSVG), which is very stable and
allows production of vectors with high titers. Furthermore, it has a
wide tropism and mediates nonselective cell entry into basically all
types of mouse, rat and human cells. However, restricting cell
entry to the cell population of interest is expected to improve safety
and efficiency of LV mediated gene transfer and to expand its
therapeutic applicability to in vivo gene therapy [3]. We have
recently developed a flexible and highly specific targeting method
for LVs, which is based on the incorporation of engineered
measles virus (MV) glycoproteins into the lentiviral envelope [4–8].
For pseudotyping of LVs, the MV glycoproteins, namely,
hemagglutinin (H) protein, responsible for receptor recognition,
and fusion (F) protein, mediating membrane fusion between virus
and host cell, have to be truncated in their cytoplasmic tails to
allow efficient incorporation into the lentiviral membrane [4]. To
interfere with cell entry via the MV receptors human CD46 and
signaling lymphocyte activation molecule (SLAM), we then
mutated the truncated H protein, which is derived from the NSe
variant of the MV vaccine strain Edmonston B, at four residues in
its ectodomain, namely Y481A, R533A, S548L and F549S [9].
The desired receptor specificity is provided by displaying a single-
chain antibody (scFv) specific for the target receptor on the
mutated H protein (Hmut-scFv). This way, very different cell
surface molecules including type1-membrane glycoproteins
(CD105), pentaspan membrane glycoproteins (CD133), mem-
brane tetraspan calcium channels (CD20) as well as multi-subunit
ion-channels (glutamate receptors, GluR) can be used for entry by
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to selectively transduce receptor-positive cell lines, but also the
corresponding target receptor-positive primary cells [4,7]. More
importantly, remarkable target specificity was observed in vivo,
upon local or systemic injection into mice [7,8], paving the way for
in vivo applications in humans. For example, modification of
CD105-positive endothelial cells to express blood clotting factors
in hemophilia patients can only be accomplished in vivo. Also direct
in vivo transduction of hematopoietic stem cells for corrections of
inherited diseases would avoid costly cell isolation and ex vivo cell
expansion. However, a potential hindrance to systemic adminis-
tration of the targeting vectors in humans is pre-existing MV-
specific immunity in almost all individuals due to vaccination or
natural infection. The MV-protective humoral immune response
is mainly directed against the H protein [10]. Rapid clearance of
targeting vectors by neutralizing a-H antibodies in the plasma may
therefore impair in vivo applications in humans.
Here, we investigated the sensitivity of targeting vectors to MV
neutralizing antibodies in human plasma. We hypothesized that
the displayed scFv and the mutations in the H ectodomain may
sterically hinder antibody binding, hence, protect the targeting
vectors against neutralization. We compared transduction effi-
ciencies of targeting vectors and non-targeting vectors pseudo-
typed with MV glycoproteins that are unmodified in their
ectodomains (MV-LV) in presence of a-MV antibody-positive
human plasma as well as monoclonal neutralizing a-H antibodies.
The data suggest that targeting vectors are partially protected
against MV neutralizing antibodies.
Results
Transduction in presence of a-MV antibody-positive
human plasma
The ability to transduce target cells in presence of a-MV
antibody-positive human plasma was investigated for targeting
vectors specific to human CD20, CD105 or CD133 (Fig. 1)a s
well as for non-targeting vectors, pseudotyped with the MV
glycoproteins derived from the NSe variant of the MV vaccine
strain Edmonston B (MVNSe-LV) or the MV wild-type strain IC-B
(MVwt-LV, Fig. 1). VSVG-LV vectors, which are not affected by
a-MV antibodies, were used as control.
Targeting vectors as well as MVNSe-LV, MVwt-LV and VSVG-
LV vectors, which transfer the genetic information for the
enhanced green fluorescent protein (EGFP), were incubated in
serial complement inactivated a-MV antibody-positive human
plasma dilutions, before the mixtures were added to the respective
CD20-, CD105- or CD133-positive target cells. The relative
transduction efficiencies compared to transduction in absence of
plasma were determined. All the targeting vectors were substan-
tially less sensitive to neutralization than MVNSe-LV and MVwt-
LV vectors. MVNSe-LV was almost completely neutralized at
plasma dilution 1:160, whereas CD20-LV, CD105-LV and
CD133-LV showed relative transduction efficiencies of 90%,
60% and 70%, respectively (Fig. 2). The CD20-LV vector showed
partial protection against MV neutralizing antibodies on Raji cells
(Fig. 2a) as well as on HT1080-CD20 cells (Fig. 2b), demon-
strating that the observed difference between targeting vectors and
MVNSe-LV was not cell line dependent.
Among the targeting vectors tested, CD20-LV showed the most
efficient escape from neutralization that came close to that of
VSVG-LV (Figs. 2a,b). CD20-LV differs from the other
targeting vectors in the configuration of the linker connecting
the aCD20-scFv with the Hmut protein. Whereas the aCD105-
and aCD133-scFvs are fused via a long flexible (G4S)3 linker to the
Hmut protein, a short factor Xa cleavage site (IEGR) is present in
CD20-LV (Fig. 1). To test if the less flexible connection between
Hmut protein and aCD20-scFv may lead to a better shielding of
the Hmut-aCD20 protein against MV neutralizing antibodies, we
deleted the (G4S)3 linker in the Hmut-aCD105 and Hmut-aCD133
constructs. However, this did not enhance the transduction
efficiency of the vectors pseudotyped with the respective Hmut-
scFv proteins (CD105w/o Linker-LV and CD133w/o Linker-LV) in
presence of a-MV antibody-positive human plasma (Figs. 2b,c).
Next, we incubated varying doses of CD20-LV, CD105-LV,
MV-LV and VSVG-LV, respectively, in a 1:80 plasma dilution.
We found that a 4-times higher MOI of MVNSe-LV had to be
applied to obtain similar transduction efficiencies on target cells as
with CD105-LV (Fig. 3a). As expected, VSVG-LV vectors were
not significantly affected by the plasma. Compared to CD20-LV,
even a 5-times higher MOI of MVNSe-LV was not sufficient to
obtain similar transduction efficiencies in the presence of 1:80
plasma (Fig. 3b). Hence, more infectious particles are needed for
MVNSe-LV and MVwt-LV (Fig. 3b) than for targeting vectors to
allow transduction in the presence of MV neutralizing antibodies.
We observed in several experiments that plasma from donors with
a high a-MV antibody titer led to stronger neutralization
Figure 1. Schematic drawing of cytoplasmic tail-truncated hemagglutinin envelope proteins used for pseudotyping of lentiviral
vectors. In the mutated hemagglutinin protein (Hmut) that is derived from the NSe variant of the measles virus (MV) vaccine strain Edmonston B,
mutations in the MV receptor recognition regions Y481A, R533A, S548L and F549S (ectodomain) are indicated by asterisks. Glycine-serine linker
((G4S)3) or the factor Xa cleavage site (IEGR) were used as linker region between Hmut and single-chain antibody (scFv). A histidine tag (H6) is present
at the scFv C-terminus. The hemagglutinin protein derived from the NSe variant of the MV vaccine strain Edmonston B that is not mutated and does
not display a scFv is labeled HNSe. The hemagglutinin protein derived from the wild-type measles virus strain IC-B is labeled Hwt. All hemagglutinin
proteins are truncated by 18 amino acids in their cytoplasmic tail (D18) to allow incorporation into the lentiviral envelope. The names of the
respective vector particles pseudotyped with the depicted H variants are indicated on the left site. w/o: without.
doi:10.1371/journal.pone.0046667.g001
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plasma dilutions of two different a-MV antibody-positive donors. (a)3 610
4 CD20-positive Raji cells (MOI 0.4) were added, or the dilutions were added
to (b) CD105/CD20-positive HT1080-CD20 (MOI 0.3) or (c) HT1080-CD133 cells (MOI 0.3) that were seeded at a density of 1.7610
4 and 0.75610
4 cells
per 96 well, respectively, 24 h before transduction. Forty-eight to 72 h later, the fraction of EGFP-positive cells was quantified by FACS analysis. The
relative transduction efficiency compared to transduction in absence of plasma (medium control) of one representative donor is shown for each cell
line.
doi:10.1371/journal.pone.0046667.g002
Figure 3. Influence of vector dose on neutralization. The indicated vector particles were incubated at varying doses in a 1:80 plasma dilution
containing (a) 1200 mU/ml or (b) 4900 mU/ml a-MV antibodies. Then, the dilutions were added to (a) CD105-positive HT1080-CD20 cells that were
seeded at a density of 1.7610
4 cells per 96 well 24 h before transduction or (b)3 610
4 CD20-positive Raji cells were added to the dilutions. Forty-
eight to 72 h later, the fraction of EGFP-positive cells was determined by FACS analysis. The relative transduction efficiency is shown (transduction
efficiency in presence of a 1:80 FCS dilution was set to 100%). Arrows indicate relative transduction efficiencies of ,1%.
doi:10.1371/journal.pone.0046667.g003
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explains why all vectors in the experiment depicted in Fig. 3b
were generally stronger neutralized than the ones shown in
Fig. 3a.
Neutralization escape of targeting vectors using equal
physical particle numbers
In comparison to MVNSe-LV vectors, the ratio of infectious to
non-infectious particles is similar for CD105-LV, but on average
2–10-fold lower for CD133- and CD20-targeting vectors [7].
Hence, by applying identical MOIs, more physical particles of the
two targeting vectors have been used. We therefore incubated
equal particle numbers of MVNSe-LV, CD20-LV and CD133-
targeting vectors, as determined by p24 assay, in serial dilutions of
a-MV antibody-positive human plasma. Transduction efficiencies
were then determined on CD133-positive HuH7 cells or CD20-
positive Raji cells. For a reliable read-out, transduction rates
should be between 10% and 50%. Above 50%, neutralization
might be underestimated due to multiple vector integrations,
below 10% small background variations might be overestimated
when calculating the relative transduction efficiency. Therefore,
cells were seeded at an optimal density for MVNSe-LV and the
targeting vectors, respectively. Using this experimental set up,
CD133-specific targeting vectors were still less sensitive to a-MV
antibody-positive human plasma than MVNSe-LV (Fig. 4a),
although escape was not as efficient as in the experiment depicted
in Fig. 2c. Hence, maybe a higher number of physical particles
was in part responsible for the neutralization escape of targeting
vectors, but other factors than antibody saturation must also play a
role. Also CD20-LV showed considerable escape, after normaliz-
ing its p24 level to that of MVNSe-LV (Fig. 4b).
Transduction in presence of a-MV antibody-negative
human serum
To verify that the observed differences between targeting
vectors and MVNSe-LV were due to MV neutralizing antibodies in
human plasma, we incubated CD20-LV, CD133-LV, CD133w/o
Linker-LV and MVNSe-LV vectors in serial dilutions of complement
inactivated a-MV antibody-negative human serum from non-
vaccinated donors without previous MV infection. Also in this
experiment same p24 levels and similar MOIs were applied. As
expected, the a-MV antibody-free serum did not neutralize the
targeting vectors or MVNSe-LV (Fig. 5). It had no significant
influence on transduction efficiency. This verifies that the observed
differences between targeting vectors and MVNSe-LV were due to
a-MV antibodies in human plasma and an at least partial
resistance of targeting vectors to these antibodies.
Transduction in presence of MV neutralizing monoclonal
antibodies
To evaluate if the mutations present in the Hmut-scFv constructs
to ablate recognition of the natural MV receptors are responsible
for the neutralization escape of the targeting vectors, we incubated
CD20-LV, CD105-LV, CD133-LV and MVNSe-LV vectors with
increasing amounts of the monoclonal neutralizing a-H antibodies
K71 and L77, respectively, and added the mixtures to the
respective target cells. For K71 escape mutations close to the
CD46 and SLAM binding sites in H have been identified, whereas
the escape mutations of L77 are more distant to the receptor
binding sites [11,12]. MVNSe-LV was entirely neutralized when
0.1 mg of K71 was applied. In contrast, the three targeting vectors
escaped neutralization by K71 almost completely (Figs. 6a–c).
Using 0.1 mg L77 antibody, MVNSe-LV as well as CD105-LV and
CD133-LV vectors were fully neutralized and CD20-LV showed a
reduced relative transduction efficiency of 30% (Figs. 6a–c).
Next, we expressed the H proteins used for pseudotyping on the
surface of HEK-293T cells. In parallel, we expressed the mutated
H protein not displaying a scFv (Hmut) and H proteins that were
not blinded for the MV receptors, but displayed the aCD20-,
aCD105- or aCD133-scFv (H-scFv) in HEK-293T cells. The cells
were then incubated with the antibodies K71 or L77 and a FITC-
conjugated secondary antibody and were analyzed by FACS. As
positive control, the primary antibody K83 [11] was used, which
was previously shown to bind the H protein [6]. K83 and L77
bound Hmut-aCD20, Hmut-aCD105, Hmut-aCD133 and Hmut
with similar efficiency, whereas K71 binding was greatly reduced.
In contrast, both K71 and L77 efficiently bound HNSe and the
different H-scFv proteins, lacking the mutation sites (Fig. 6d, Fig.
S1). Hence, the neutralization escape of the targeting vectors from
the K71 antibody is likely due to the inability of the antibody to
efficiently bind to Hmut-scFv constructs.
Figure 4. Influence of particle amount on neutralization. Equal amounts of vector particles as determined by p24 ELISA were incubated in
serial plasma dilutions of two different a-MV antibody-positive donors. The dilutions were added to (a) CD133-positive HuH7 cells that were seeded
24 h before transduction at a density of 1.0610
4 (CD133-specific vectors) and 5.0610
4 (MVNSe-LV) cells per 96 well, respectively, to apply similar MOIs.
Alternatively, the dilutions were added to (b) 1.0610
4 (CD20-LV) and 5.0610
4 (MVNSe-LV) CD20-positive Raji cells, respectively. Seventy-two h later,
the percentage of EGFP-positive cells was determined by FACS analysis. The relative transduction efficiency compared to transduction in absence of
plasma of one representative donor is shown.
doi:10.1371/journal.pone.0046667.g004
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indicated vector types were incubated in serial serum dilutions of an a-MV antibody-negative donor. Then, (a)1 610
4 (CD20-LV) and 2610
5 (MVNSe-
LV) CD20-positive Raji cells were added, respectively, or the dilutions were added to (b) CD133-positive HuH7 cells. These were seeded at a density of
1.0610
4 (targeting vectors) and 5.0610
4 (MVNSe-LV) cells per 96 or 48 well, respectively, 24 h before transduction, to apply similar MOIs of vector
particles. Forty-eight to 72 h later, the percentage of EGFP-positive cells was determined by FACS analysis. As control, medium without serum was
used.
doi:10.1371/journal.pone.0046667.g005
Figure 6. Targeting vectors are protected against the neutralizing antibody K71. Equal amounts of physical particles of the indicated
vector types were incubated in presence of increasing amounts of antibody K71 (K71-Ab; putative epitope near the mutation sites in Hmut-scFv
constructs) and L77 (L77-Ab; putative epitope distant to the mutation sites in Hmut-scFv constructs), respectively, in a final volume of 100 ml. After
incubation at room temperature for 1 h, (a)3 610
4 (CD20-LV) or 4.5610
5 (MVNSe-LV) CD20-positive Raji cells were added, or the vectors were added
to (b) 9.3610
4 (CD105-LV) or 3.4610
4 (MVNSe-LV) CD105-positive HT1080 cells or (c) 3.4610
4 (CD133-LV) or 2.7610
4 (MVNSe-LV) CD133-positive HuH7
cells, to apply an MOI of 0.25 for each vector type. Forty-eight hours later, the fraction of EGFP-positive cells was quantified by FACS analysis. Mean
values (n=3) and s.d. of the relative transduction efficiency compared to transduction in absence of antibody is shown for each cell line. (d) The
indicated H proteins were expressed on the surface of HEK-293T cells. The control antibody K83 and the antibodies K71 and L77 were incubated with
the cells, respectively, and a FITC-labeled secondary antibody was used to detect antibody binding to the different H proteins by FACS analysis. The
percentage of FITC-positive cells subtracted by the staining of secondary antibody alone is shown. Arrows indicate 0% cell staining.
doi:10.1371/journal.pone.0046667.g006
Neutralization Protected Targeting Vectors
PLOS ONE | www.plosone.org 5 October 2012 | Volume 7 | Issue 10 | e46667Discussion
Targeting vectors are especially suited for in vivo administrations
as they are specific for their target cell populations, leaving other
cells unmodified. The targeting vectors investigated here are
pseudotyped with engineered MV glycoproteins displaying scFvs
specific for cell surface receptors of interest. Point mutations in the
H protein ectodomain ablate recognition of the native MV
receptors CD46 and SLAM. The recently identified third MV
receptor, which was found to be nectin-4 [13,14], and to mediate
MV infection of lung epithelial cells, played no role in this study as
all cells used were nectin-4 negative (data not shown).
We demonstrate here that lentiviral targeting vectors pseudo-
typed with engineered MV glycoproteins are partially protected
against a-MV antibodies in human plasma.
As most MV neutralizing antibodies are directed against H and
not F protein [10], it is most likely that the modifications
introduced in H for receptor targeting reduced antibody binding.
Due to the extensive glycosylation of the H protein, the antibody
response is mostly directed towards a limited number of
immunodominant domains including the receptor binding sites,
with a strong antibody response to the SLAM and a weaker
response to the CD46 recognition site [15,16]. Both regions are
mutated in the H protein used for lentiviral retargeting. These
mutations might have destroyed the epitopes of neutralizing
antibodies interfering with receptor recognition. This hypothesis is
supported by the results depicted in Figure 6. Whereas the K71
antibody was not able to neutralize the targeting vectors, the L77
antibody neutralized all vector types. Based on escape mutants of
the MV strain CAM/RB, amino acid residues conferring escape
from the antibodies K71 (E492K, S550P) and L77 (P377Q,
M378K) had been identified [11,12]. Amino acid residues S550
and M378 are also present in the H protein derived from the
Edmonston B strain used in this study. In the H protein crystal
structure [16], amino acid residue S550 is located close to the
mutations R533A, S548L and F549S present in Hmut and Hmut-
scFv to render them deficient for use of the natural MV receptors.
In contrast, residue M378, which is important for L77 binding, is
distant to all four mutations. Hence, the epitope of K71 is likely
destroyed in Hmut-scFv constructs, preventing binding of the
antibody. The observation that K71 can bind the H-scFv
constructs, but not the Hmut protein further supports this
hypothesis (Fig. 6d, Fig. S1). Recently, Le ´vy et al. [17]
demonstrated that MVNSe-LV vectors that efficiently transduce
resting lymphocytes [18,19], representing promising candidates for
in vivo applications, could be protected in vitro against monoclonal
neutralizing antibodies by introducing mutations into the Noose
and NE epitopes in H. These epitopes form beside the receptor
recognition regions further binding sites for neutralizing antibodies
[20,21]. Interestingly, an additional glycosylation site at position
N416, which is present in newly emerged MV-D genotypes, was
required to gain also protection against a-MV antibody-positive
human serum [17]. Probably the introduced glycosylation
sterically hinders binding of neutralizing antibodies. Likewise,
besides the introduced mutations, the displayed scFv on Hmut-scFv
protein in targeting vectors may contribute to protection against
neutralizing antibodies in human plasma. In the absence of
structural information about the H protein C-terminus [22], its
exact position relative to H protein cannot be predicted. It is
however likely that the flexible H protein C-terminus allows the
scFv to sterically hinder neutralizing antibody binding not only in
the receptor recognition regions but also in other sites. Finally, it is
conceivable that effective neutralization of the vectors is difficult in
the absence of antibodies directed against the scFv itself. Such
antibodies are expected to efficiently prevent target receptor
binding and scFv mediated cell entry.
Interestingly, CD20-LV escaped neutralization more efficiently
than CD105-LV and CD133-LV. We excluded that the higher
flexibility of the linker peptide between Hmut protein and
aCD105- or aCD133-scFv influenced neutralization escape
(Figs. 2b,c). Differences in the scFv framework and thus the
scFv 3D structure could in principle explain subtle differences in
neutralization escape. However, the framework regions between
the three scFvs, especially between aCD133- and aCD20-scFvs,
are very similar. The CD133- and CD20-specific scFvs are both of
murine origin, the heavy chains are even derived from the same
germ line. Alternatively, receptor topology may have an influence
on neutralization as all three target receptors belong to different
protein classes: CD20 is a membrane tetraspan calcium channel,
whereas CD105 is a type1-membrane glycoprotein and CD133 a
pentaspan membrane glycoprotein. Possibly, the epitope on CD20
is better accessible for the aCD20-scFv even when antibodies are
bound to H protein than the epitopes for the CD133- and CD105-
specific scFv. This hypothesis is in line with our observation that
only CD20-LV escaped neutralization by L77 to a certain extent,
although L77 bound Hmut-aCD20 as efficient as Hmut-aCD105
and Hmut-aCD133 (Figure 6).
We demonstrate here for three different targeting vectors that
they are all partially protected against MV neutralizing antibodies
in human plasma. Thus, our data indicate that targeting vectors in
general can escape neutralization by a-MV antibodies at least to a
certain extent, which suggests that single systemic applications may
be possible despite pre-existing a-MV immunity. For repeated
cycles of in vivo vector administration, pseudotyping of LVs with
engineered H and F glycoproteins of other paramyxoviruses, such
as the Tupaia paramyxovirus (TPMV) is an option [23].
Materials and Methods
Ethics Statement
The research has been approved by the Ethics Committee of
the University Hospital Frankfurt, Germany. Written informed
consent was obtained from each donor.
Plasmid construction
The plasmids encoding the truncated HNSe,H wt or Hmut
protein as well as the plasmids encoding the truncated Hmut
protein displaying the aCD20-scFv via the factors Xa site (pCG-
Hmut-aCD20) or the aCD105-scFv and aCD133-scFv via a (G4S)3
linker (Fig. 1), respectively, were described previously [4,6,7]. For
generation of constructs pCG-Hmut-aCD105 and pCG-Hmut-
aCD133 without (G4S)3 linker, the respective scFv coding regions
were cloned into the SfiI and NotI digested pCG-Hmut-aCD20
backbone thereby replacing the factor Xa-aCD20-scFv coding
region in pCG-Hmut-aCD20. For generation of the plasmids pCG-
H-aCD20, pCG-H-aCD105 and pCG-H-aCD133, the scFv
coding regions were cloned into the SfiI and NotI digested
pCG-HNSeD18His backbone.
The H protein plasmids were purified with the EndoFreeH
Plasmid Maxi Kit (Qiagen, Hilden, Germany), whereas all other
plasmids used for vector particle production were purified by the
PlasmidFactory GmbH & Co. KG, Bielefeld, Germany.
Cultivation of cell lines
The culture of HEK-293T, Raji, HT1080 and HT1080-CD20
cells has been described previously [4]. HT1080 cells stably
transfected with a CD133 expression plasmid (HT1080-CD133)
[7] were cultured in Dulbecco’s modified Eagle medium (DMEM)
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G418. HuH7 cells (JCRB cell bank) were cultured in DMEM
supplemented with 10% FCS and 2 mM L-glutamine.
Vector particle production and titration
Lentiviral vector particles were produced by polyethyleneimine
(PEI) based transfection of HEK-293T cells. For this purpose,
2610
7 cells were seeded 24 h before transfection into a T175 flask.
On the day of transfection, medium was replaced with 10 ml of
DMEM supplemented with 15% FCS and 2 mM L-glutamine.
For targeting vectors, 1.35 mgo fM VH mut-scFv protein expression
plasmid, 4 mg of pCG-FcD30 [4], 14.4 mg of packaging plasmid
pCMVDR8.9 [24] and 15.2 mg of transfer vector plasmid pSEW
[25], encoding the enhanced green fluorescent protein (EGFP),
were mixed with 2.3 ml DMEM without supplements. For MV-
LV vectors, 1.35 mgo fM VH NSe protein or 4 mgM VH wt protein
expression plasmid and 9.4 mg or 6.7 mg of pCG-FcD30,
respectively, together with 9.1 mg pCMVDR8.9 and 15.2 mg
pSEW were mixed with 2.3 ml DMEM without supplements. In
parallel, 140 ml of 18 mM PEI and 2.2 ml DMEM without
supplements were mixed. The PEI mixture and the DNA mixture
were combined, vortexed and incubated for 20 min at room
temperature (25uC), before the transfection mixture was added to
the cells. Twenty-four h later, medium was exchanged against
16 ml fresh DMEM supplemented with 10% FCS and 2 mM L-
glutamine. The cell supernatant containing the pseudotyped
vector particles was filtered 24 h later (0.45-mm filter) and
concentrated by ultracentrifugation over a 20% (wt/vol) sucrose
cushion (100 000 g for 3 h at 4uC). The supernatant was
discarded and the pellet was resuspended in 60 ml PBS. Vector
particles pseudotyped with VSVG were produced by co-transfec-
tion of 6.13 mg pMD.G2 (kindly provided by Didier Trono,
Tronolab, Lausanne, Switzerland), 11.4 mg pCMVDR8.9 and
17.5 mg pSEW. Targeting vectors and control vectors were titrated
together on the same cell line used for the neutralization assays.
EGFP-positive cells were determined by FACS analysis and vector
stock titers were calculated as described previously [4,7]. The p24
values of the vector preparations were determined using the HIV-
1 p24 antigen ELISA RETROtek kit (ZeptoMetrix Corporation,
Buffalo, NY, USA).
Expression of H protein variants in HEK-293T cells
1610
6 HEK-293T cells were seeded in each well of a 6 well
plate. Twenty-four hours later, the cells were transfected by
Lipofectamine and Plus Reagent (Invitrogen, Darmstadt, Ger-
many) with 3 mg per well of the plasmids encoding the different H
protein variants or the empty control plasmid pCG-1 according to
the manufacturer’s instructions. After 24 h, the cells were used for
antibody staining and FACS analysis.
Neutralization assays
Human plasma was collected from MV vaccinated healthy
donors using the BD Vacutainer
TM CPT
TM system with sodium
citrate (BD, Heidelberg, Germany). The MV antibody titers of all
donors were in the range of 1200–4900 mU/ml. a-MV antibody-
negative serum was collected from healthy non-MV vaccinated
donors without previous MV infection. All samples were
complement inactivated by incubation at 56uC for 30 min. For
antibody binding, the indicated vector particles were incubated in
a 96 well plate for 20 min at 4uC in serial dilutions of plasma or
serum. Before adding the dilutions to the respective cell lines, they
were pre-warmed at 37uC for 5–10 min. Alternatively, the
indicated vector particles were incubated for 1 h at RT in
presence of different concentrations of the neutralizing a-H
antibody K71 or L77 [11,12], before they were added to the
cells. Plates were incubated for 3 h at 37uC before an exchange
with fresh medium was performed. Forty-eight to 72 h later, the
percentage of EGFP-positive cells was determined by FACS
analysis. The relative transduction efficiency compared to
transduction in absence of plasma/serum/antibody was deter-
mined. In another experiment, a constant plasma dilution was
used (1:80) and the amount of incubated vector particles was
varied. As control, vector particles were incubated in parallel in a
1:80 dilution of complement inactivated FCS. The relative
transduction efficiency compared to transduction in presence of
FCS was determined.
Flow cytometry
Flow cytometry was performed as described previously [4].
Briefly, adherent cells were detached by incubation with 50–
500 ml PBS-trypsin solution. Trypsin digestion was stopped by
adding 200–1000 ml medium containing 10% FCS. Cells in
suspension were then transferred into Micronic tubes (Micronic
Europe B.V., Lelystad, The Netherlands) and after the addition of
600 ml FACS washing buffer (PBS, 1% FCS, 0.1% NaN3), they
were pelleted at 310 g for 3 min and 4uC. The cells were washed
once more in 900 ml FACS washing buffer and finally resuspended
in 100 ml PBS/1% paraformaldehyde. Alternatively, the cells were
incubated after the second washing step for 1 h with the antibody
K83 (1:10), K71 (1 mg) or L77 (1 mg) [11,12], respectively. After
two additional washing steps, they were incubated for 20 min with
the FITC-labeled goat polyclonal secondary antibody to mouse
IgG-Fc (1:50, Abcam plc, Cambridge, UK), before they were
washed twice and finally fixed in 100 ml PBS/1% paraformalde-
hyde. Data were obtained with the LSR II FACS machine (BD,
Heidelberg, Germany) and analysed with the FACSDiva software
(BD, Heidelberg, Germany). Gates were set such that they
contained less than 1% of the cells from the negative control cell
population, which were untransduced cells.
Supporting Information
Figure S1 K71 antibody does not bind Hmut and Hmut-
scFv proteins. The indicated H proteins were expressed on the
surface of HEK-293T cells. As control, HEK-293T cells
transfected with the empty expression plasmid pCG-1 were used.
The control antibody K83 and the antibodies K71 and L77 were
incubated with the cells, respectively, and a FITC-labeled
secondary antibody was used to detect antibody binding to the
different H proteins. The percentage of FITC-positive cells was
determined by FACS analysis. When cells were incubated with the
secondary mouse IgG-Fc specific antibody alone, it bound
unspecifically to the displayed scFv on the H proteins, which
was defined as background binding.
(TIF)
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